CA3042528C - Novel phenyl propionic acid derivatives and uses thereof - Google Patents
Novel phenyl propionic acid derivatives and uses thereof Download PDFInfo
- Publication number
- CA3042528C CA3042528C CA3042528A CA3042528A CA3042528C CA 3042528 C CA3042528 C CA 3042528C CA 3042528 A CA3042528 A CA 3042528A CA 3042528 A CA3042528 A CA 3042528A CA 3042528 C CA3042528 C CA 3042528C
- Authority
- CA
- Canada
- Prior art keywords
- oxy
- inden
- dihydro
- pyridin
- hex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2016-0171541 | 2016-12-15 | ||
| KR20160171541 | 2016-12-15 | ||
| KR10-2017-0171228 | 2017-12-13 | ||
| KR1020170171228A KR102007633B1 (ko) | 2016-12-15 | 2017-12-13 | 신규 페닐 프로피온 산 유도체 및 이의 용도 |
| PCT/KR2017/014757 WO2018111012A1 (en) | 2016-12-15 | 2017-12-14 | Novel phenyl propionic acid derivatives and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3042528A1 CA3042528A1 (en) | 2018-06-21 |
| CA3042528C true CA3042528C (en) | 2022-03-08 |
Family
ID=62559593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3042528A Active CA3042528C (en) | 2016-12-15 | 2017-12-14 | Novel phenyl propionic acid derivatives and uses thereof |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11225472B2 (enExample) |
| EP (1) | EP3555076B1 (enExample) |
| JP (1) | JP6892922B2 (enExample) |
| KR (1) | KR102007633B1 (enExample) |
| CN (1) | CN110049984B (enExample) |
| AU (1) | AU2017374460B2 (enExample) |
| BR (1) | BR112019012433A2 (enExample) |
| CA (1) | CA3042528C (enExample) |
| DK (1) | DK3555076T3 (enExample) |
| ES (1) | ES2948485T3 (enExample) |
| FI (1) | FI3555076T3 (enExample) |
| HU (1) | HUE062468T2 (enExample) |
| IL (1) | IL267239B (enExample) |
| MX (1) | MX2019007071A (enExample) |
| MY (1) | MY198292A (enExample) |
| PH (1) | PH12019501251A1 (enExample) |
| PL (1) | PL3555076T3 (enExample) |
| PT (1) | PT3555076T (enExample) |
| RS (1) | RS64259B1 (enExample) |
| RU (1) | RU2760266C2 (enExample) |
| SI (1) | SI3555076T1 (enExample) |
| WO (1) | WO2018111012A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220112185A1 (en) * | 2016-12-15 | 2022-04-14 | Ildong Pharmaceutical Co., Ltd. | Novel phenyl propionic acid derivatives and uses thereof |
| KR102007633B1 (ko) * | 2016-12-15 | 2019-08-06 | 일동제약(주) | 신규 페닐 프로피온 산 유도체 및 이의 용도 |
| WO2019160882A1 (en) | 2018-02-13 | 2019-08-22 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| WO2019191624A1 (en) | 2018-03-29 | 2019-10-03 | Arbutus Biopharma, Inc. | Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same |
| WO2019204609A1 (en) | 2018-04-19 | 2019-10-24 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| BR112020026746A2 (pt) | 2018-07-13 | 2021-03-30 | Gilead Sciences, Inc. | Composto, composição farmacêutica, métodos para inibir pd-1, pd-l1 e/ou a interação de pd-1/pd-l1 e para tratar câncer, e, kit para tratar ou prevenir câncer ou uma doença ou condição. |
| CN112955435B (zh) | 2018-10-24 | 2024-09-06 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| JP2022552655A (ja) | 2019-10-07 | 2022-12-19 | キャリーオペ，インク． | Ｇｐｒ１１９アゴニスト |
| PH12022552277A1 (en) | 2020-02-28 | 2024-03-04 | Kallyope Inc | Gpr40 agonists |
| JP2023526625A (ja) | 2020-05-19 | 2023-06-22 | キャリーオペ，インク． | Ａｍｐｋアクチベーター |
| CN116390925A (zh) | 2020-06-26 | 2023-07-04 | 卡尔优普公司 | Ampk活化剂 |
| EP4329756A1 (en) * | 2021-04-29 | 2024-03-06 | Ildong Pharmaceutical Co., Ltd. | Pharmaceutical composition comprising gpr40 agonist and sglt-2 inhibitor |
| WO2022269439A1 (en) * | 2021-06-21 | 2022-12-29 | Ildong Pharmaceutical Co., Ltd. | Method of controlling blood sugar level and treatment of diabetes and related conditions |
| WO2023080299A1 (ko) * | 2021-11-08 | 2023-05-11 | 일동제약(주) | 페닐 프로피온 산 유도체의 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물 |
| KR20240084229A (ko) * | 2022-12-06 | 2024-06-13 | 유노비아 주식회사 | 안정성이 향상된 gpr40 효현제를 유효성분으로 포함하는 약제학적 조성물 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4594611B2 (ja) * | 2002-11-08 | 2010-12-08 | 武田薬品工業株式会社 | 受容体機能調節剤 |
| EA011010B1 (ru) * | 2004-02-27 | 2008-12-30 | Эмджен, Инк. | Соединения, модулирующие рецептор gpr40, фармацевтическая композиция, способ лечения заболеваний, чувствительных к модулированию рецептора gpr40 (варианты), способ модулирования функции gpr40 (варианты) и способ модулирования циркулирующей концентрации инсулина |
| EP1726580A4 (en) * | 2004-03-15 | 2008-02-13 | Takeda Pharmaceutical | AMINOPHNYLPROPANO ACID DERIVATIVE |
| CA2620476A1 (en) * | 2005-06-02 | 2006-12-07 | Jenrin Discovery | Mao-b inhibitors useful for treating obesity |
| WO2007033002A1 (en) * | 2005-09-14 | 2007-03-22 | Amgen Inc. | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
| JP5055852B2 (ja) | 2006-06-21 | 2012-10-24 | 住友大阪セメント株式会社 | 鉄資源の回収方法 |
| HUE025363T2 (en) * | 2010-12-01 | 2016-02-29 | Boehringer Ingelheim Int | Indanyl Oxide Hydrobenzofuranylacetic Acids that can be used to treat metabolic syndrome |
| JP2013147443A (ja) * | 2012-01-18 | 2013-08-01 | Daiichi Sankyo Co Ltd | β置換カルボン酸誘導体 |
| US8633182B2 (en) | 2012-05-30 | 2014-01-21 | Boehringer Ingelheim International Gmbh | Indanyloxyphenylcyclopropanecarboxylic acids |
| JP6533778B2 (ja) * | 2013-09-26 | 2019-06-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｇｐｒ４０アゴニストとしてのインダニルオキシジヒドロベンゾフラニル酢酸誘導体を調製するための方法および中間体 |
| WO2017180457A1 (en) | 2016-04-11 | 2017-10-19 | Janssen Pharmaceutica Nv | Gpr40 agonists in anti-diabetic drug combinations |
| KR102007633B1 (ko) * | 2016-12-15 | 2019-08-06 | 일동제약(주) | 신규 페닐 프로피온 산 유도체 및 이의 용도 |
| US20220112185A1 (en) * | 2016-12-15 | 2022-04-14 | Ildong Pharmaceutical Co., Ltd. | Novel phenyl propionic acid derivatives and uses thereof |
| EP4329756A1 (en) * | 2021-04-29 | 2024-03-06 | Ildong Pharmaceutical Co., Ltd. | Pharmaceutical composition comprising gpr40 agonist and sglt-2 inhibitor |
| WO2022269439A1 (en) * | 2021-06-21 | 2022-12-29 | Ildong Pharmaceutical Co., Ltd. | Method of controlling blood sugar level and treatment of diabetes and related conditions |
| US20230022803A1 (en) * | 2021-06-25 | 2023-01-26 | Ildong Pharmaceutical Co., Ltd. | Novel crystalline form of gpr40 agonist |
-
2017
- 2017-12-13 KR KR1020170171228A patent/KR102007633B1/ko active Active
- 2017-12-14 SI SI201731367T patent/SI3555076T1/sl unknown
- 2017-12-14 CA CA3042528A patent/CA3042528C/en active Active
- 2017-12-14 HU HUE17880872A patent/HUE062468T2/hu unknown
- 2017-12-14 DK DK17880872.1T patent/DK3555076T3/da active
- 2017-12-14 RU RU2019121871A patent/RU2760266C2/ru active
- 2017-12-14 WO PCT/KR2017/014757 patent/WO2018111012A1/en not_active Ceased
- 2017-12-14 MX MX2019007071A patent/MX2019007071A/es unknown
- 2017-12-14 BR BR112019012433A patent/BR112019012433A2/pt not_active Application Discontinuation
- 2017-12-14 RS RS20230456A patent/RS64259B1/sr unknown
- 2017-12-14 FI FIEP17880872.1T patent/FI3555076T3/fi active
- 2017-12-14 US US16/467,654 patent/US11225472B2/en not_active Expired - Fee Related
- 2017-12-14 EP EP17880872.1A patent/EP3555076B1/en active Active
- 2017-12-14 PT PT178808721T patent/PT3555076T/pt unknown
- 2017-12-14 IL IL267239A patent/IL267239B/en unknown
- 2017-12-14 MY MYPI2019003388A patent/MY198292A/en unknown
- 2017-12-14 ES ES17880872T patent/ES2948485T3/es active Active
- 2017-12-14 JP JP2019531649A patent/JP6892922B2/ja not_active Expired - Fee Related
- 2017-12-14 CN CN201780074801.4A patent/CN110049984B/zh not_active Expired - Fee Related
- 2017-12-14 PL PL17880872.1T patent/PL3555076T3/pl unknown
- 2017-12-14 AU AU2017374460A patent/AU2017374460B2/en not_active Ceased
-
2019
- 2019-06-06 PH PH12019501251A patent/PH12019501251A1/en unknown
-
2021
- 2021-11-10 US US17/523,652 patent/US11731961B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3042528C (en) | Novel phenyl propionic acid derivatives and uses thereof | |
| AU2017284160B2 (en) | FXR (NR1H4) modulating compounds | |
| CA3030377C (en) | Nitrogen-containing tricyclic compounds and uses thereof in medicine | |
| KR102692309B1 (ko) | Fxr (nr1h4) 조정 화합물 | |
| JP2021528394A (ja) | Ｇｌｐ−１受容体アゴニストおよびその使用 | |
| WO2013122029A1 (ja) | 芳香環化合物 | |
| US20220112185A1 (en) | Novel phenyl propionic acid derivatives and uses thereof | |
| US20250368619A1 (en) | Substituted tetrahydrocyclohepta[e]indole derivatives, processes for their preparation and therapeutic uses thereof | |
| NZ750495A (en) | Compositions for the treatment of pulmonary fibrosis | |
| EP4508028B1 (en) | Novel substituted 4-amino-4-oxo-but-2-enyl derivatives, processes for their preparation and therapeutic uses thereof | |
| NZ753053B2 (en) | Phenyl propionic acid derivatives and uses thereof | |
| TW202532411A (zh) | Ｇｌｐ－１受體激動劑及其用途 | |
| HK40109860B (en) | Fxr (nr1h4) modulating compounds | |
| HK40109860A (en) | Fxr (nr1h4) modulating compounds | |
| JP2025513063A (ja) | 新規置換フッ化ビニル－ｎ－プロピル－ピロリジン化合物、それを調製するためのプロセス及びその治療的使用 | |
| JP2025513853A (ja) | 新規の置換フッ化ｎ－プロピル－ピロリジン及びｎ－プロピル－アゼチジン化合物、それらの調製のためのプロセス及びその治療的使用 | |
| HK40055654A (en) | Isoxazole compound as fxr agonist and pharmaceutical compositions comprising same | |
| HK40055654B (en) | Isoxazole compound as fxr agonist and pharmaceutical compositions comprising same | |
| HK40029408B (en) | Azetidine derivatives as fxr (nr1h4) modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190501 |